In addition, we established that SRE in combination with anti-PD-1 antibodies significantly reduces CRC tumor growth via tumor-infiltrating CD8+ T cell activities in an hPD-L1 MC38 cell-bearing hPD-1 knockin mouse model. The gene discussed is CD8A; the disease is neoplasm.